Neopharmed Gentili
Healthcare
HQ: Milan, Italy
Investors: 4
An Italian pharmaceutical company focused on the commercialization of high-value therapeutic solutions.
Investors (4)
| Fund | Status | Entry Date | Stage | Source |
|---|---|---|---|---|
| Ardian | Current | 2022 | - | Website |
| Anima Alternative SGR | Current | - | - | Website |
| Narval Investimenti | Current | - | - | Website |
| Renaissance Partners | Current | - | - | Website |
Signals (1)
2025-06-27
Neopharmed Gentili signed an agreement to acquire BioCryst's ORLADEYO business in Europe for up to $264M, including $250M upfront and milestone payments
Source: BioCryst